Further Results from Bone Therapeutics ALLOB Phase I/IIA Delayed-Union Fracture Trial

Bone Therapeutics announced positive efficacy results for the 2nd patient cohort in its Phase I/IIA trial of ALLOB® allogeneic bone cell therapy product for the treatment of delayed-union fractures. Of eight patients treated, seven met primary endpoints of the trial within 6-month follow-up.

The ongoing Phase I/IIA study is a 6-month...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us